Pharmarise Holdings Corporation
Symbool: 2796.T
JPX
659
JPYMarktprijs vandaag
24.8104
Koers/Winst Verhouding
-0.9523
Koers/Winst Groei Verhouding
7.41B
MRK Kapitalisatie
- 0.02%
DIV Rendement
Pharmarise Holdings Corporation (2796-T) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 4742 | 3991 | 4604 | ||||||||||||||||
balance-sheet.row.short-term-investments | 0 | -1926 | -2079 | -2427 | ||||||||||||||||
balance-sheet.row.net-receivables | 0 | 605 | 479 | 926 | ||||||||||||||||
balance-sheet.row.inventory | 0 | 2290 | 2302 | 2587 | ||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 317 | 315 | 260 | ||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 11372 | 10878 | 10546 | ||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 6007 | 6355 | 6432 | ||||||||||||||||
balance-sheet.row.goodwill | 0 | 2748 | 3220 | 4025 | ||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 501 | 408 | 438 | ||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 3249 | 3628 | 4463 | ||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 2008 | 2139 | 2488 | ||||||||||||||||
balance-sheet.row.tax-assets | 0 | 778 | 741 | 786 | ||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 4 | ||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 12042 | 12863 | 14173 | ||||||||||||||||
balance-sheet.row.other-assets | 0 | 7 | 5 | 5 | ||||||||||||||||
balance-sheet.row.total-assets | 0 | 23421 | 23746 | 24724 | ||||||||||||||||
balance-sheet.row.account-payables | 0 | 4252 | 4109 | 4609 | ||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3677 | 2490 | 2819 | ||||||||||||||||
balance-sheet.row.tax-payables | 0 | 333 | 429 | 573 | ||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 5461 | 7422 | 7878 | ||||||||||||||||
Deferred Revenue Non Current | 0 | -42 | -31 | 0 | ||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 747 | 691 | 645 | ||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 6600 | 8571 | 9001 | ||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 432 | 551 | 700 | ||||||||||||||||
balance-sheet.row.total-liab | 0 | 16435 | 17048 | 18393 | ||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||||||||
balance-sheet.row.common-stock | 0 | 1298 | 1274 | 1251 | ||||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4014 | 3811 | 3494 | ||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 226 | 203 | 208 | ||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 1343 | 1319 | 1268 | ||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 6881 | 6607 | 6221 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 23421 | 23746 | 24724 | ||||||||||||||||
balance-sheet.row.minority-interest | 0 | 105 | 91 | 110 | ||||||||||||||||
balance-sheet.row.total-equity | 0 | 6986 | 6698 | 6331 | ||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||||||||
Total Investments | 0 | 82 | 60 | 61 | ||||||||||||||||
balance-sheet.row.total-debt | 0 | 9138 | 9912 | 10697 | ||||||||||||||||
balance-sheet.row.net-debt | 0 | 4396 | 5921 | 6093 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 1049 | 1322 | 1202 | ||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 1224 | 1308 | 1344 | ||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 513 | -1465 | -139 | ||||||||||||||||
cash-flows.row.account-receivables | 0 | 482 | -1319 | 365 | ||||||||||||||||
cash-flows.row.inventory | 0 | 68 | 286 | 56 | ||||||||||||||||
cash-flows.row.account-payables | 0 | 13 | -500 | -582 | ||||||||||||||||
cash-flows.row.other-working-capital | 0 | -50 | 68 | 22 | ||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -266 | -452 | -462 | ||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -542 | -466 | -552 | ||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -180 | 2 | -116 | ||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -2 | -2 | ||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 383 | 12 | ||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 19 | -209 | -418 | ||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -703 | -292 | -1076 | ||||||||||||||||
cash-flows.row.debt-repayment | 0 | -2419 | -2636 | -2857 | ||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 1737 | 2199 | ||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -36 | ||||||||||||||||
cash-flows.row.dividends-paid | 0 | -131 | -131 | -129 | ||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 1478 | -2 | 95 | ||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -1072 | -1034 | -728 | ||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | -2 | 0 | -1 | ||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 743 | -613 | 140 | ||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 4734 | 3991 | 4604 | ||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 3991 | 4604 | 4464 | ||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 2520 | 713 | 1945 | ||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -542 | -466 | -552 | ||||||||||||||||
cash-flows.row.free-cash-flow | 0 | 1978 | 247 | 1393 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 52030 | 51608 | 52324 | ||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 43896 | 43491 | 44256 | ||||||||||||||||
income-statement-row.row.gross-profit | 0 | 8134 | 8117 | 8068 | ||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-expenses | 0 | 32 | -7 | 21 | ||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 6695 | 6596 | 6821 | ||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 50591 | 50087 | 51077 | ||||||||||||||||
income-statement-row.row.interest-income | 0 | 1 | 1 | 1 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 55 | 65 | 75 | ||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -390 | -200 | -45 | ||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 32 | -7 | 21 | ||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -390 | -200 | -45 | ||||||||||||||||
income-statement-row.row.interest-expense | 0 | 55 | 65 | 75 | ||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1224 | 1308 | 1344 | ||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||||||
income-statement-row.row.operating-income | 0 | 1438 | 1520 | 1246 | ||||||||||||||||
income-statement-row.row.income-before-tax | 0 | 1049 | 1322 | 1202 | ||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 702 | 863 | 782 | ||||||||||||||||
income-statement-row.row.net-income | 0 | 333 | 447 | 426 |
Vaak gestelde vragen
Wat is Pharmarise Holdings Corporation (2796.T) totale activa?
Pharmarise Holdings Corporation (2796.T) totale activa is 23421000000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.156.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.006.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.026.
Wat is Pharmarise Holdings Corporation (2796.T) nettowinst (netto-inkomen)?
De nettowinst is 333000000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 9138000000.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 6695000000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.